Home
Name
Alectinib
Alternate Names
Alecensa
ALK inhibitor CH5424802
Abbreviations
None
Category
Chemotherapy
Subcategory
ALK Inhibitor
NSC Number
None
Primary Site
Lung
Histology
Non-small cell lung cancer (NSCLC)
Remarks
UPDATE: December 11, 2015 FDA granted accelerated approval to alectinib for the treatment of anaplastic lymphoma kinase (ALK) positive metastatic non-small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib (Xalkori).
November 6, 2017: FDA granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
November 6, 2017: FDA granted regular approval to alectinib for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test.
Coding
This drug should be coded
